• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps

    2/11/25 9:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPB alert in real time by email

    Upstream's 2025 Automotive & Smart Mobility Cybersecurity Report reveals that 60% of cyber incidents could affect thousands to millions of connected vehicles, with massive-scale attacks more than tripling; the report emphasizes that current regulatory requirements are insufficient to address expanding cyber risks.

    ANN ARBOR, Mich., Feb. 11, 2025 /PRNewswire/ -- Upstream Security, the leading provider of cloud-based cybersecurity and data management platform purpose-built for automotive, smart mobility, and IoT ecosystem, today released the 2025 Automotive & Smart Mobility Cybersecurity Report. The annual report, returning for its seventh year, highlights that despite the increased regulatory attention, the number, scale, and severity of cyber attacks continues to grow, showing a false sense of security and resilience. Automakers and mobility stakeholders have to go beyond regulations to address the threats causing serious implications for safety, operational availability and data privacy.

    The report revealed that in 2024, 60% of cybersecurity incidents in the automotive and smart mobility sectors affected thousands to millions of mobility assets, including vehicles, EV charging stations, smart mobility apps, and connected devices. Notably, massive-scale incidents—each impacting millions of vehicles—more than tripled, rising from 5% in 2023 to 19% in 2024. This sharp increase highlights the urgent need for organizations to prioritize resilience by extending their cybersecurity efforts beyond regulatory compliance.

    The rise of software-defined and autonomous vehicles has introduced new vulnerabilities, leading to a widening cybersecurity gap. Additionally, critical infrastructure in smart mobility devices, like EV chargers and fleet management systems, has expanded the attack surface and magnified the stakes. Mobility-specific ransomware attacks surged in 2024 causing unprecedented disruptions with 108 reported ransom attacks and 214 data breaches. One of the most impactful incidents was a ransomware attack in June on a leading US-based software provider used by 15,000 automotive dealerships which resulted in halted operations for nearly three weeks, estimating losses at $1.02 billion.

    "The cybersecurity landscape across the Automotive and Smart Mobility ecosystem is poised to become more complex than ever," said Yoav Levy, CEO and co-founder of Upstream. "Cyber threats are evolving faster than the industry is prepared to handle, outpacing regulation-driven measures. Threat actors have already shifted toward large-scale, sophisticated and AI-powered attack methods, targeting not only vehicles but also interconnected systems such as EV charging infrastructure, API-driven apps, and smart mobility IoT devices. This growing attack surface demands a transformative and proactive approach to cybersecurity."

    Cyberattacks in 2024 became more sophisticated and frequent, targeting vehicles and backend systems, as well as smart mobility platforms, devices, and applications. 65% of publicly reported cyber incidents were carried out by black hat actors with malicious intent. 92% of attacks were executed remotely, supporting the surge in scale and impact, of which 85% were long-range and did not require any physical proximity to the targeted asset. The ecosystem experienced a significant surge in telematics and application server attacks in 2024— 43% of incidents in 2023 rising to 66% in 2024.

    In addition to monitoring publicly reported cyber incidents, Upstream's AutoThreat® team monitors the deep and dark web for threat actors targeting connected vehicles, mobility applications and devices. When zooming in on deep and dark web activities carried out by black hat hackers, 70% activities had the potential to impact thousands to millions of mobility assets and over 76% targeted multiple stakeholders and had a global reach.

    Additional key findings in the report include:

    • 2024 saw 409 new incidents (up from 295 in 2023), contributing to a total of 1,877 documented cases since 2010.
    • The dramatic rise in incidents is largely attributed to a sharp escalation in ransomware attacks targeting the mobility sector.
    • Data and privacy-related incidents accounted for 60% of 2024 incidents, up 20% from 2023.
    • The percentage of incidents involving car system manipulation and control of vehicle systems increased dramatically in 2024, accounting for over 35% of incidents.

    The report further delves into a range of topics including China's strategic automotive investments and impact on the cyber landscape, EV charging infrastructure risks, 2024's attack vectors and today's regulatory reality. Download the full 2025 Upstream Global Automotive & Smart Mobility Cybersecurity Report here.

    About Upstream Security

    Upstream delivers a cloud-based, AI-powered data management platform purpose-built for connected vehicles, smart mobility, and IoT ecosystem. The Upstream Platform transforms fragmented, distributed mobility data into centralized, structured, and contextualized data lakes, unlocking its full potential. By leveraging this data, Upstream empowers customers with advanced, AI-driven applications across various use cases, including proactive vehicle quality management, cybersecurity detection and response (XDR), fraud prevention, observability, usage-based insurance, and more.

    Upstream Media Contact

    Mushkie Meyer

    [email protected]

    US: +1 914 336 4035

    UK: +44 203 769 4034

     

    Cision View original content:https://www.prnewswire.com/news-releases/automotive-security-leaders-must-take-immediate-action-to-mitigate-the-surging-cyber-threatsupstream-report-reveals-critical-gaps-302373309.html

    SOURCE Upstream

    Get the next $UPB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPB

    DatePrice TargetRatingAnalyst
    12/18/2025$51.00Outperform
    Mizuho
    11/18/2025$40.00Outperform
    Evercore ISI
    10/14/2025$47.00Buy
    Truist
    11/5/2024$75.00Overweight
    Piper Sandler
    11/5/2024$38.00Overweight
    JP Morgan
    11/5/2024Outperform
    William Blair
    11/5/2024Buy
    TD Cowen
    More analyst ratings

    $UPB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chimovits Erez bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:19:30 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:17:52 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ai Upstream Llc bought $19,975,000 worth of shares (1,175,000 units at $17.00) and converted options into 4,319,410 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:05:04 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    SEC Filings

    View All

    Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Upstream Bio, Inc. (0002022626) (Filer)

    2/11/26 9:17:02 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Upstream Bio, Inc. (0002022626) (Filer)

    2/11/26 6:38:51 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.

    SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

    11/14/25 4:27:07 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

    – Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – WALTHAM, Mass., March 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). The

    3/1/26 9:45:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Participate in Upcoming March Investor Conferences

    WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Boston, MAWednesday, March 4, 2026, Fireside Chat - 9:50 a.m. ET2026 Leerink Partners Global Healthcare Conference, Miami, FLMonday, March 9, 2026, Fireside Chat - 1:40 p.m. ET Live webcasts of the presentations will be available under the Events tab on the Investors section o

    2/25/26 7:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

    – Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens – – Verekitug was generally well tolerated, with a safety profile consistent with prior studies – – Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term extension study – – Upstream Bio to advance verekitug into Phase 3 trials in severe asthma and CRSwNP following planned regulatory interactions – – Management will host a live webcast today at 8:00

    2/11/26 6:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Upstream Bio with a new price target

    Mizuho initiated coverage of Upstream Bio with a rating of Outperform and set a new price target of $51.00

    12/18/25 9:11:57 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI initiated coverage on Upstream Bio with a new price target

    Evercore ISI initiated coverage of Upstream Bio with a rating of Outperform and set a new price target of $40.00

    11/18/25 8:28:41 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Upstream Bio with a new price target

    Truist initiated coverage of Upstream Bio with a rating of Buy and set a new price target of $47.00

    10/14/25 8:54:39 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Houghton Adam was granted 25,000 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    1/6/26 5:15:04 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Deykin Aaron was granted 32,000 shares, increasing direct ownership by 2,024% to 33,581 units (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    1/6/26 5:15:09 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Ambrose Allison was granted 17,000 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    1/6/26 5:15:05 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Leadership Updates

    Live Leadership Updates

    View All

    Upstream Bio Appoints Stacy Price as Chief Technology Officer

    WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

    5/20/25 7:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio Appoints Allison Ambrose as General Counsel

    WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

    12/17/24 8:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Financials

    Live finance-specific insights

    View All

    Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    – In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

    9/2/25 6:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl

    9/1/25 5:00:00 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    11/7/24 9:24:55 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Upstream Bio Inc.

    SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

    10/22/24 4:06:27 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    10/18/24 6:10:56 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care